BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23686863)

  • 1. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome.
    Rodriguez-Tolrà J; Torremadé J; di Gregorio S; Del Rio L; Franco E
    Andrology; 2013 Jul; 1(4):570-5. PubMed ID: 23686863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome.
    Rodriguez-Tolrà J; Torremadé Barreda J; del Rio L; di Gregorio S; Franco Miranda E
    Aging Male; 2013 Dec; 16(4):184-90. PubMed ID: 24083636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of testosterone replacement in hypogonadal men.
    Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study.
    Bouloux PM; Legros JJ; Elbers JM; Geurts TB; Kaspers MJ; Meehan AG; Meuleman EJ;
    Aging Male; 2013 Jun; 16(2):38-47. PubMed ID: 23581697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
    Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
    BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
    Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
    Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men.
    Aminorroaya A; Kelleher S; Conway AJ; Ly LP; Handelsman DJ
    Eur J Endocrinol; 2005 Jun; 152(6):881-6. PubMed ID: 15941928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
    Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
    Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.
    Fairfield WP; Finkelstein JS; Klibanski A; Grinspoon SK
    J Clin Endocrinol Metab; 2001 May; 86(5):2020-6. PubMed ID: 11344201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
    Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study.
    Durnez A; Paternotte S; Fechtenbaum J; Landewé RB; Dougados M; Roux C; Briot K
    J Rheumatol; 2013 Oct; 40(10):1712-8. PubMed ID: 23950191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone.
    Amory JK; Watts NB; Easley KA; Sutton PR; Anawalt BD; Matsumoto AM; Bremner WJ; Tenover JL
    J Clin Endocrinol Metab; 2004 Feb; 89(2):503-10. PubMed ID: 14764753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients.
    Strollo F; Strollo G; Morè M; Magni P; Macchi C; Masini MA; Carucci I; Celotti F; Ruscica M; Gentile S
    Aging Male; 2013 Jun; 16(2):33-7. PubMed ID: 23517433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome.
    Tahani N; Nieddu L; Prossomariti G; Spaziani M; Granato S; Carlomagno F; Anzuini A; Lenzi A; Radicioni AF; Romagnoli E
    Endocrine; 2018 Aug; 61(2):327-335. PubMed ID: 29696556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of hypogonadism and testosterone-enhancing therapy on alkaline phosphatase and bone mineral density.
    Dabaja AA; Bryson CF; Schlegel PN; Paduch DA
    BJU Int; 2015 Mar; 115(3):480-5. PubMed ID: 25046796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 12-month observation of testosterone replacement effectiveness in a general population of men.
    Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
    Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.